PATENT CLAIM ANALYSIS

Application Number: 16296766
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["424", "130100"]

Abstract:
Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 12 , X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Claim (Index 1):
A method of treating a condition selected from cancer of the bladder, cancer of the uterus, cancer of the colon, cancer of the esophagus, cancer of the liver, ovarian cancer, prostate cancer, pancreatic cancer, auto-immune diseases, and diseases of the immune system, in a subject in need thereof, comprising administration of an effective amount of compound of formula (I): wherein:\n A represents linear or branched (C 1 -C 6 )alkyl, linear or branched (C 2 -C 6 )alkenyl, linear or branched (C 2 -C 6 )alkynyl, linear or branched (C 1 -C 6 )alkoxy, \u2014S\u2014(C 1 -C 6 )alkyl, linear or branched (C 1 -C 6 )polyhaloalkyl, hydroxy, cyano, \u2014NR 10 R 10 \u2032, -Cy 6 , or halogen; \n R 1 , R 2 , R 3 , R 4  and R 5  independently of one another represent hydrogen, halogen, linear or branched (C 1 -C 6 )alkyl, linear or branched (C 2 -C 6 )alkenyl, linear or branched (C 2 -C 6 )alkynyl, linear or branched (C 1 -C 6 )polyhaloalkyl, hydroxy, linear or branched (C 1 -C 6 )alkoxy, \u2014S\u2014(C 1 -C 6 )alkyl, cyano, nitro, -alkyl(C 0 -C 6 )\u2014NR 8 R 8 \u2032, \u2014O-Cy 1 , -alkyl(C 0 -C 6 )-Cy 1 , -alkenyl(C 2 -C 6 )-Cy 1 , -alkynyl(C 2 -C 6 )-Cy 1 , \u2014O-alkyl(C 1 -C 6 )\u2014R 9 , \u2014C(O)\u2014OR 8 , \u2014O\u2014C(O)\u2014R 8 , \u2014C(O)\u2014NR 8 R 8 \u2032, \u2014NR 8 \u2014C(O)\u2014R 8 \u2032, \u2014NR 8 \u2014C(O)\u2014OR 8 \u2032, -alkyl(C 1 -C 6 )\u2014NR 8 \u2014C(O)\u2014R 8 \u2032, \u2014SO 2 \u2014NR 8 R 8 \u2032, or \u2014SO 2 -alkyl(C 1 -C 6 ), \n or the substituents of one of the pairs (R 1 , R 2 ), (R 2 , R 3 ), (R 1 , R 3 ), (R 4 , R 5 ) when grafted onto two adjacent carbon atoms, together with the carbon atoms carrying them, form an aromatic or non-aromatic ring having from 5 to 7 ring members, which ring may have from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, and which ring may be optionally substituted by a group selected from linear or branched (C 1 -C 6 )alkyl, \u2014NR 10 R 10 \u2032, -alkyl(C 0 -C 6 )-Cy 1 , and oxo; \n X represents a carbon or a nitrogen atom; \n R 6  represents hydrogen, linear or branched (C 1 -C 8 )alkyl, aryl, heteroaryl, arylalkyl(C 1 -C 6 ), heteroarylalkyl(C 1 -C 6 ); \n R 7  represents linear or branched (C 1 -C 6 )alkyl, linear or branched (C 2 -C 6 )alkenyl, linear or branched (C 2 -C 6 )alkynyl, -Cy 3 , -alkyl(C 1 -C 6 )-Cy 3 , -alkenyl(C 2 -C 6 )-Cy 3 , -alkynyl(C 2 -C 6 )-Cy 3 , -Cy 3 -Cy 4 , -alkynyl(C 2 -C 6 )\u2014O-Cy 3 , -Cy 3 -alkyl(C 0 -C 6 )\u2014O-alkyl(C 0 -C 6 )-Cy 4 , halogen, cyano, \u2014C(O)\u2014R 11 , or \u2014C(O)\u2014NR 11 R 11 \u2032; \n R 8  and R 8 \u2032 independently of one another represent hydrogen, linear or branched (C 1 -C 6 )alkyl, or -alkyl(C 0 -C 6 )-Cy 1 , \n or (R 8 , R 8 \u2032), together with the nitrogen atom carrying them, form an aromatic or non-aromatic ring having from 5 to 7 ring members, which ring may have, in addition to the nitrogen atom, from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, wherein the nitrogen in question may be substituted by hydrogen, or linear or branched (C 1 -C 6 )alkyl and wherein one or more of the carbon atoms of the possible substituents, may be deuterated; \n R 9  represents -Cy 1 , -Cy 1 -alkyl(C 0 -C 6 )-Cy 2 , -Cy 1 -alkyl(C 0 -C 6 )\u2014O-alkyl(C 0 -C 6 )-Cy 2 , -Cy 1 -alkyl(C 0 -C 6 )\u2014NR 8 -alkyl(C 0 -C 6 )-Cy 2 , -Cy 1 -Cy 2 -O-alkyl(C 0 -C 6 )-Cy 5 , \u2014NR 8 R 8 \u2032, \u2014C(O)\u2014NR 8 R 8 \u2032, \u2014OR 8 , \u2014NR 8 \u2014C(O)\u2014R 8 \u2032, \u2014O-alkyl(C 1 -C 6 )\u2014OR 8 , \u2014SO 2 \u2014R 8 , \u2014C(O)\u2014OR 8 , or \u2014NH\u2014C(O)\u2014NH\u2014R 8 ; \n R 10 , R 10 \u2032, R H  and R u \u2032 independently of one another represent hydrogen or optionally substituted linear or branched (C 1 -C 6 )alkyl; \n R 12  represents hydrogen or hydroxy; \n Cy 1 , Cy 2 , Cy 3 , Cy 4 , Cy 5  and Cy 6  independently of one another, represent cycloalkyl, heterocycloalkyl, aryl or heteroaryl; \n n is an integer equal to 0 or 1; \n it being understood that:\n \u201caryl\u201d means a phenyl, naphthyl, biphenyl, indanyl, or indenyl; \n \u201cheteroaryl\u201d means any mono- or bi-cyclic group having from 5 to 10 ring members, having at least one aromatic moiety and having from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen; \n \u201ccycloalkyl\u201d means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, \n \u201cheterocycloalkyl\u201d means any mono- or bi-cyclic non-aromatic carbocyclic group having from 3 to 10 ring members, and having from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems; \n wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, may be optionally substituted by from 1 to 4 groups selected from:\n linear or branched (C 1 -C 6 )alkyl, optionally substituted by a group selected from:\n linear or branched (C 1 -C 6 )alkoxy, optionally substituted by linear or branched (C 1 -C 6 )alkoxy, \n linear or branched (C 1 -C 6 )polyhaloalkyl, \n hydroxy, \n halogen, \n oxo, \n \u2014NR\u2032R\u2033, \n \u2014O\u2014C(O)\u2014R\u2032, and \n \u2014CO\u2014NR\u2032R\u2033; \n \n linear or branched (C 2 -C 6 )alkenyl; \n linear or branched (C 2 -C 6 )alkynyl, optionally substituted by linear or branched (C 1 -C 6 )alkoxy; \n linear or branched (C 1 -C 6 )alkoxy, optionally substituted by a group selected from:\n linear or branched (C 1 -C 6 )alkoxy, \n linear or branched (C 1 -C 6 )polyhaloalkyl, \n linear or branched (C 2 -C 6 )alkynyl, \n \u2014NR\u2032R\u2033, and \n hydroxy; \n \n (C 1 -C 6 )alkyl-S\u2014, optionally substituted by linear or branched (C 1 -C 6 )alkoxy; \n hydroxy; \n oxo (or N-oxide where appropriate); \n nitro; \n cyano; \n \u2014C(O)\u2014OR\u2032; \n \u2014O\u2014C(O)\u2014R\u2032; \n \u2014CO\u2014NR\u2032R\u2033; \n \u2014NR\u2032R\u2033; \n \u2014(C\u2550NR\u2032)\u2014OR\u2033; \n linear or branched (C 1 -C 6 )polyhaloalkyl; \n trifluoromethoxy; and \n halogen; \n wherein R\u2032 and R\u2033 independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, optionally substituted by linear or branched (C 1 -C 6 )alkoxy; and wherein one or more of the carbon atoms of the preceding possible substituents, may be deuterated, or an enantiomer, a diastereoisomer, an atropoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base, wherein the compound of formula (I) is administered alone or in combination with one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 99.0
- Lexical Diversity: 1.59574
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14576683', '15492306', '15738601', '16069891', '15737479']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8551530045002854
- 35 USC 102 Novelty (BERT): 0.673708883617651
- Combined Prediction Score: 0.837008592412022
- Mean Citation Score: 685.7307800000002
- Max Citation Score: 719.5483
- Similarity Product: 662.4563493030429

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test